Mentor Capital Cancer Immunotherapy Index Up 97% in 2013

SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 97.4% during 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 annual period the biotech indices averaged a 54.8% gain.

Inovio (481%), Provectus (330%) and Celldex (261%) have led the sector in gains during the January thru September 2013 period. Celldex ($2.0 Billion) represents 39% of the market capitalization of the fifteen member Cancer Immunotherapy Index which has a combined total share value of $5.1 Billion.

The Mentor Capital Cancer Immunotherapy Index companies and their performance for the twelve months of 2013 follow: Galena Biopharma Corporation (NASDAQ:GALE) +224.18%, NewLink Genetics Corporation (NASDAQ:NLNK) +76.08%, Vical Incorporated (NASDAQ:VICL) -59.45%, Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) +480.58%, Dendreon (NASDAQ:DNDN) -43.48%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) -51.56%, Agenus (NASDAQ:AGEN) -35.61, Oncothyreon (NASDAQ:ONTY) -8.33%, Biovest International (OTCMKTS:BVTIQ) -100.00%, Celldex Therapeutics (NASDAQ:CLDX) +260.80%, Northwest Biotherapeutics (NASDAQ:NWBO) +45.85%, CEL – SCI Corp. (NYSEMKT:CVM) -78.15% , Generex Biotechnology (OTCBB:GNBT) +14.40% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (OTCMKTS:PVCT) +330.36% and Advaxis, Inc. (OTCBB:ADXSD) +13.07 - all for an average 2013 annual gain of +97.40%.

Mentor Capital, Inc. created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at Currently, Mentor Capital targets investment primarily toward cannabis related companies.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

Mentor Capital, Inc.
Chester Billingsley, CEO
(760) 788 - 4700

Source: Mentor Capital, Inc.